Abstract:: The impact of genetic variants on gene expression has been intensely studied at the transcription level, yielding invaluable insights into the association between genes and the risk of complex disorders, such as schizophrenia (SCZ). However, the downstream impact of these variants and the molecular mechanisms connecting transcription variation to disease risk are not well understood. : We quantitated ribosome occupancy in prefrontal cortex samples of the BrainGVEX cohort. Together with transcriptomics and proteomics data from the same cohort, we performed cis-Quantitative Trait Locus (QTL) mapping and identified 3,253 expression QTLs (eQTLs), 1,344 ribosome occupancy QTLs (rQTLs), and 657 protein QTLs (pQTLs) out of 7,458 genes from 185 samples. Of the eQTLs identified, only 34% have their effects propagated to the protein level. Further analysis on the effect size of prefrontal cortex eQTLs identified from an independent dataset clearly replicated the post-transcriptional attenuation of eQTL effects. We identified omics-specific QTLs and investigated their potential in driving disease risks. Using a variant based approach, we found expression-specific QTLs (esQTLs) for 1,553 genes, ribosome-occupancy-specific QTLs (rsQTLs) for 155 genes, and protein-specific QTLs (psQTLs) for 161 genes. Among these omics-specific QTL, 38 showed strong colocalization with brain associated disorder GWAS signals, 29 of them are esQTLs. Because a gene could contain multiple QTL signals, each could either be shared across omics or omics-specific, we aggregated QTL signals from each omics for each gene and found 11 brain associated disorder risk genes that are driven predominantly by omics-specific QTL, all of them are driven by variants impacting transcriptional regulation. This gene-based approach also enabled us to categorize risk genes containing both omics-specific and shared QTL signals. The limited number of GWAS colocalization discoveries from gene-based omics-specific mapping, however, prompted us to take a complementary approach to investigate the functional relevance of genes driven predominantly by attenuated eQTL signals. Using S-PrediXcan we identified 74 SCZ risk genes across the three omics, 30% of which were novel, and 67% of these risk genes were confirmed to be causal in a MR-Egger test using data from the corresponding omics. Notably, 52 out of the 74 risk genes were identified using eQTL data and 68% of these SCZ-risk-gene-driving eQTLs show little to no evidence of driving corresponding variations at the protein level. : The effect of eQTLs on gene expression in the prefrontal cortex is commonly attenuated post-transcriptionally. Many of the attenuated eQTLs still correlate with GWAS signals of brain associated complex disorders, indicating the possibility that these eQTL variants drive disease risk through mechanisms other than regulating protein expression level. Further investigation is needed to elucidate the mechanistic link between attenuated eQTLs and brain associated complex disorders.

Spatial Expression Pattern of ZNF391 Gene in the Brains of Patients with Schizophrenia, Bipolar Disorders or Major Depressive Disorder Identifies New Cross-Disorder Biotypes: A Trans-Diagnostic, Top-Down Approach

Intelligence As Proxy Phenotype Providing Insight into the Heterogeneity of Schizophrenia

Connecting genomic results for psychiatric disorders to human brain cell types and regions reveals convergence with functional connectivity

Unraveling NEK4 As a Potential Drug Target in Schizophrenia and Bipolar I Disorder: A Proteomic and Genomic Approach.

Integrated Transcriptome Analysis Reveals Novel Molecular Signatures for Schizophrenia Characterization.

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Transcriptomic Similarity Informs Neuromorphic Deviations in Depression Biotypes.

Genome-Transcriptome-Functional Connectivity-Cognition Link Differentiates Schizophrenia from Bipolar Disorder

Shared genetic architecture of cortical thickness alterations in major depressive disorder and schizophrenia

Commonality in Dysregulated Expression of Gene Sets in Cortical Brains of Individuals with Autism, Schizophrenia, and Bipolar Disorder

Cross-disorder Genomewide Analysis of Schizophrenia, Bipolar Disorder, and Depression.

Regional neural functional efficiency across schizophrenia, bipolar disorder, and major depressive disorder: a transdiagnostic resting-state fMRI study

The impact of common variants on gene expression in the human brain: from RNA to protein to schizophrenia risk

Identifying novel proteins underlying bipolar disorder via integrating pQTLs of the plasma, CSF, and brain with GWAS summary data

Individualized gray matter morphological abnormalities uncover two robust transdiagnostic biotypes

Investigating the Shared Genetic Architecture Between Psychiatric Disorders and Executive Function

Postmortem transcriptional profiling reveals widespread increase in inflammation in schizophrenia: a comparison of prefrontal cortex, striatum, and hippocampus among matched tetrads of controls with subjects diagnosed with schizophrenia, bipolar or major depressive disorder

Integrating Genome-Wide Association Study and Expression Quantitative Trait Locus Study Identifies Multiple Genes and Gene Sets Associated with Schizophrenia

Brain transcriptional regulatory architecture and schizophrenia etiology converge between East Asian and European ancestral populations

SNX29, a New Susceptibility Gene Shared with Major Mental Disorders in Han Chinese Population

Identifying Common Genome-Wide Risk Genes for Major Psychiatric Traits